Received: 31 July 2019
Accepted: 9 October 2019
First Online: 6 November 2019
Ethics approval and consent to participate
: Not applicable. Ethics approval was obtained prior to analysis of clinical data as reported in Cancer, 2015, and as stated in the manuscript text. The work presented in this manuscript however, is a cost-effectiveness model and analysis of combined carbon ion therapy plus IMRT versus IMRT alone. Costs were derived based on clinical data reported in Cancer 2015. Actual individual billing data were neither retrieved not available for this analysis. Hence “ethics approval and consent to participate” does not really apply.
: Not applicable.
: Dr. AD Jensen has no competing interest. Prof. Dr. Dr. J. Debus is CEO of Heidelberg Ion Beam Therapy Centre (HIT).